| Type |
Project |
Development Stage |
Characteristic / Advantage |
| New Drug |
Ulcerative Colitis
(DW2007) |
Phase 2a |
Contributing to an anti-inflammatory effect and the stabilization of intestinal microorganisms
Expect the possibility of remission and the effect of maintenance |
Allergic Asthma/Rhinitis
(DW2008) |
Phase 1 |
An oral medication with both bronchial inflammation inhibiting and dilating effects
Having superior efficacy in anti-leukotriene and possible steroid combination therapy |
| IMD |
Zabolante |
Non-clinical / Phase 3 |
Verifying the expansion of pneumonia indication and development possibility of injectable drugs with its excellent antibacterial ability against respiratory infectious and resistant bacteria |
Cardiovascular
(DW6009) |
Phase 1 |
A block bust drug complex frequently prescribed in combination to cardiovascular disease patients |
Alzheimer
(DW6010) |
Phase 1 |
A complex to alleviate moderate to severe Alzheimer's disease |
Anti-Inflammatory Analgesic drug
(DW6008) |
Phase 1 |
Increasing patient convenience by acting on the NSAID-related upper gastrointestinal side effects |
| Functional Food |
Cognitive Function Improvement
(DW2009) |
Clinical trial |
Developing new lactobacillus (C29, etc.) material to improve cognitive function
Verifying clinical efficacy and safety with aging-friendly functional food |
Body Fat Improvement
(DW2010) |
Clinical trial |
Developing new lactobacillus (OK67, etc.) materials for body fat improvement
Verifying non-clinical body fat reduction effect and safety |
Atopy Improvement
(DW2011) |
Candidate |
Safely and effectively improving skin immune function with the raw materials listed in the Korean Food Standards Codex |